Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 10/2018

01-10-2018 | Original Article

Prognostic factors in stereotactic body radiotherapy of lung metastases

Authors: K. J. Borm, M. Oechsner, PhD, K. Schiller, J. C. Peeken, H. Dapper, S. Münch, L. Kroll, S. E. Combs, M. N. Duma

Published in: Strahlentherapie und Onkologie | Issue 10/2018

Login to get access

Abstract

Purpose

The aim of this study was to evaluate prognostic factors in patients with lung metastases who undergo lung stereotactic body radiotherapy (SBRT).

Materials and methods

A total of 87 patients with 129 lung metastases who underwent SBRT between November 2004 and May 2012 were enrolled in this retrospective study. The patient collective consisted of 54 men (62.1%) and 33 women (37.9%); the median age was 65 years (range 36–88). The Karnofsky performance index was ≥70% (median 90%) for all cases, but one (60%). Adverse effects were categorized using the CTCAE 4.0 classification system. Retrospective analyses regarding patients’ characteristics, progression-free survival (PFS), overall survival (OS), disease-specific survival (DSS), and local tumor control rates (LTC) were performed.

Results

On univariate and multivariate analysis OS, DSS, and PFS were significantly (p < 0.05) better for patients with ≤3 lung metastases; no extrathoracic metastases at the time of the SBRT; a gross tumor volume (GTV) <7.7 cm3 and patients that received a staging that included positron emission tomography with fluorine 18 fluorodeoxyglucose/computed tomography (FDG-PET/CT) imaging. Furthermore, a longer OS was observed if newly diagnosed metastases during follow-up were limited to the lung (median survival: 43.7 months versus 21.7 months; p = 0.023).

Conclusion

The number and pattern of metastases, and the size of the target volume are strong predictors for the outcome of patients receiving SBRT of lung tumors. FDG-PET/CT should be part of pretherapeutic staging before SBRT.
Literature
1.
Saito Y et al (2002) Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg 124(5):1007–1013CrossRef
2.
Pfannschmidt J et al (2003) Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experiences in 167 patients. J Thorac Cardiovasc Surg 126(3):732–739CrossRef
3.
Corbin KS, Hellman S, Weichselbaum RR (2013) Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 31(11):1384–1390CrossRef
4.
Rusthoven KE et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27(10):1579–1584CrossRef
5.
Stera S et al (2017) Breathing-motion-compensated robotic guided stereotactic body radiation therapy. Patterns of failure analysis. Strahlenther Onkol 194(2):143–155CrossRef
6.
Wulf J et al (2005) Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol 77(1):83–87CrossRef
7.
Hof H et al (2007) Stereotactic single-dose radiotherapy of lung metastases. Strahlenther Onkol 183(12):673–678CrossRef
8.
De Rose F et al (2016) Clinical outcome of stereotactic ablative body radiotherapy for lung metastatic lesions in non-small cell lung cancer oligometastatic patients. Clin Oncol (R Coll Radiol) 28(1):13–20CrossRef
9.
Rieber J et al (2017) Influence of institutional experience and technological advances on outcome of stereotactic body radiation therapy for oligometastatic lung disease. Int J Radiat Oncol Biol Phys 98(3):511–520CrossRef
10.
Tanadini-Lang S et al (2017) Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. Radiother Oncol 123(2):182–188CrossRef
11.
Navarria P et al (2014) Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiat Oncol 9(1):91CrossRef
12.
Okunieff P et al (2006) Stereotactic Body Radiation Therapy (SBRT) for lung metastases. Acta Oncol 45(7):808–817CrossRef
13.
Ricardi U et al (2012) Stereotactic body radiation therapy for lung metastases. Lung Cancer 75(1):77–81CrossRef
14.
Nuyttens JJ et al (2015) Stereotactic body radiation therapy for oligometastases to the lung: a phase 2 study. Int J Radiat Oncol Biol Phys 91(2):337–343CrossRef
15.
Onishi H et al (2004) Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101(7):1623–1631CrossRef
16.
Norihisa Y et al (2008) Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys 72(2):398–403CrossRef
17.
Inoue T et al (2013) Stereotactic body radiotherapy for pulmonary metastases. Prognostic factors and adverse respiratory events. Strahlenther Onkol 189(4):285–292CrossRef
18.
Tree AC et al (2013) Stereotactic body radiotherapy for oligometastases. Lancet Oncol 14(1):e28–e37CrossRef
19.
Salama JK et al (2012) Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 118(11):2962–2970CrossRef
20.
Zhang Y et al (2011) Stereotactic body radiation therapy favors long-term overall survival in patients with lung metastases: five-year experience of a single-institution. Chin Med J (Engl) 124(24):4132–4137
21.
Kang JK et al (2010) Oligometastases confined one organ from colorectal cancer treated by SBRT. Clin Exp Metastasis 27(4):273–278CrossRef
22.
Thibault I et al (2014) Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution’s comprehensive experience. Clin Oncol (R Coll Radiol) 26(11):713–719CrossRef
23.
Dhami G et al (2017) Framework for radiation pneumonitis risk stratification based on anatomic and perfused lung dosimetry. Strahlenther Onkol 193(5):410–418CrossRef
Metadata
Title
Prognostic factors in stereotactic body radiotherapy of lung metastases
Authors
K. J. Borm
M. Oechsner, PhD
K. Schiller
J. C. Peeken
H. Dapper
S. Münch
L. Kroll
S. E. Combs
M. N. Duma
Publication date
01-10-2018
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 10/2018
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-018-1335-x

Other articles of this Issue 10/2018

Strahlentherapie und Onkologie 10/2018 Go to the issue

Original Article

Stereotactic radiotherapy for choroidal melanomas by means of HybridArc™

Original Article

Automatic replanning of VMAT plans for different treatment machines: A template-based approach using constrained optimization

Editorial

Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math

Original Article

MRI-based high-precision irradiation in an orthotopic pancreatic tumor mouse model

Literatur kommentiert

Hochrisiko-Endometriumkarzinom: Immer eine adjuvante Radiochemotherapie?

Literatur kommentiert

Die Radiotherapie des Pleuramesothelioms – Klinische Praxisleitlinie der American Society of Clinical Oncology